NovoCure Ltd
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
NovoCure Ltd
13.87
−0.74 · −5.08%
−7.48%
vs ±17.7% implied · ×0.42
shaded = implied · ▲▼ = realized
Linked news
Bull3
Bear2
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $263.2M | 16.62% | +1.78% |
| BlackRockindex-like | $203.2M | 12.83% | +1.67% |
| Soleus | $150.2M | 9.48% | −5.52% |
| Vanguard Portfolioindex-like | $95.0M | 6.00% | +0.33% |
| Vanguardindex-like | $74.3M | 4.69% | +4.73% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $263.2M | 16.62% | +1.78% |
| BlackRockindex-like | $203.2M | 12.83% | +1.67% |
| Soleus | $150.2M | 9.48% | −5.52% |
| Vanguard Portfolioindex-like | $95.0M | 6.00% | +0.33% |
| Vanguardindex-like | $74.3M | 4.69% | +4.73% |
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of NovoCure Ltd's 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of NovoCure Ltd's 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
Expected move
Inputsspot 14.61exp Jan 15ATM strike 15ATM straddle 3.22IV 62%